Ixazomib: A Review in Relapsed and/or Refractory Multiple Myeloma.

about

Delineating Crosstalk Mechanisms of the Ubiquitin Proteasome System That Regulate Apoptosis.

P2860

Q50316561-45F83E3E-AA29-4A8F-BC44-35D8042622BB

P2860

Ixazomib: A Review in Relapsed and/or Refractory Multiple Myeloma.

Item

http://www.wikidata.org/entity/Q39403929

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Ixazomib: A Review in Relapsed and/or Refractory Multiple Myeloma.

@en

Ixazomib: A Review in Relapsed and/or Refractory Multiple Myeloma.

@nl

type

Item

label

Ixazomib: A Review in Relapsed and/or Refractory Multiple Myeloma.

@en

Ixazomib: A Review in Relapsed and/or Refractory Multiple Myeloma.

@nl

prefLabel

Ixazomib: A Review in Relapsed and/or Refractory Multiple Myeloma.

@en

Ixazomib: A Review in Relapsed and/or Refractory Multiple Myeloma.

@nl

P1476

Ixazomib: A Review in Relapsed and/or Refractory Multiple Myeloma.

@en

P2093

Zaina T Al-Salama

http://www.w3.org/2001/XMLSchema#string

P2860

Novel agents in the treatment of multiple myeloma: a review about the future

Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma.

Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Phase 1 study of ixazomib alone or combined with lenalidomide-dexamethasone in Japanese patients with relapsed/refractory multiple myeloma.

In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells

Population Pharmacokinetic Analysis of Ixazomib, an Oral Proteasome Inhibitor, Including Data from the Phase III TOURMALINE-MM1 Study to Inform Labelling.

The Effect of a High-Fat Meal on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma.

A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end-stage renal disease requiring haemodialysis

Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment

P2888

s11523-017-0504-7

P304

535-542

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11523-017-0504-7

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Karly Garnock-Jones

Lesley J Scott

P577

2017-06-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28660423

http://www.w3.org/2001/XMLSchema#string

Ixazomib: A Review in Relapsed and/or Refractory Multiple Myeloma.

about

P2860

P2860

Ixazomib: A Review in Relapsed and/or Refractory Multiple Myeloma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698